Cognition Therapeutics Q2 net loss $4.7M; positive SEQUEL topline for CT1812

COGNITION THERAPEUTICS INC

2023-Q2 EPS reported -$0.37

Net loss of $4.7M ($0.16/sh) vs $5.8M ($0.25/sh) in Q2 2022; R&D expense $8.5M.
Cash and equivalents $37.2M; NIA grants remaining $81.8M; cash runway through Q3 2024.
Positive topline results from Phase 2 SEQUEL qEEG study; full data expected Q4 2023.
540-patient Phase 2 START trial (early Alzheimer's) recruiting; MAGNIFY dry AMD dosing started.
Published SNAP study confirming sigma-2 receptor target engagement of CT1812.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COGNITION THERAPEUTICS INC reported the second quarter ended June 30, 2023 results: net income net loss of $4.7 million or $(0.16) per basic and diluted share.

Period: the second quarter ended June 30, 2023
Net income: net loss of $4.7 million or $(0.16) per basic and diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $4.7 million or $(0.16) per basic and diluted share for the second quarter ended June 30, 2023, compared to a net loss of $5.8 million or $(0.25) per basic and diluted share during the same period in 2022.

View on SEC.gov

Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-23-088580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.